Praxis Precision Medicines Inc Hits 52-Week High on EMBOLD Study Success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 05 Dec 25
Source: 424B5
Praxis Precision Medicines, Inc. shares surged by 34.16%, reaching a 52-week high following positive results from the EMBOLD study.
The EMBOLD study demonstrated significant efficacy for relutrigine in treating SCN2A and SCN8A developmental epileptic encephalopathies, prompting an early stop recommendation from the Data Monitoring Committee. This breakthrough is expected to accelerate the drug's market entry, addressing a critical need in the epilepsy treatment landscape.
With the upcoming presentation of topline results at the American Epilepsy Society Annual Meeting and a confirmed FDA meeting, the company is well-positioned for future growth, potentially leading to substantial economic returns.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 456.71 USD with a low forecast of 95.00 USD and a high forecast of 843.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 309.920
Low
95.00
Averages
456.71
High
843.00
Current: 309.920
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
